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Abstract
Background: Hip fracture is associated with increased mortality. Our aim was to study potential risk factors, including
osteoporosis, associated with short- and long-term mortality in a prospectively recruited cohort of fragility hip fracture
patients.
Methodology/Principal Findings: Fragility hip fracture patients aged .50 years admitted to a county hospital in Southern
Norway in 2004 and 2005 were consecutively identified and invited for assessment. Patients with high energy or
pathological fractures, patients with confusion, serious infections or who were non-residents in the catchment area were
excluded. As part of a clinical routine, data were collected using questionnaires. Standardized bone density measurements
of lumbar spine and hip were performed. Potential predictors of hip fracture mortality were tested using univariate and
multivariate logistic regression analysis. A total of 432 hip fracture patients (129 males and 303 females) were prospectively
identified. Among them 296 (85 males and 211 females) patients [mean age 80.7 (SD 9.1)] were assessed at the Osteoporosis
center. Variables independently associated with short-term mortality (after 1 year) were in females older age [Odds Ratio
(OR) 6.95] and in males older age (OR 5.74) and pulmonary disease (OR 3.20), whereas no associations were observed with
mortality for 3 months after the fragility hip fracture. Variables independently associated with 5 years mortality in males was
osteoporosis (OR 3.91) and older age (OR 6.95), and in females was dementia (OR 4.16) and older age (OR 2.80).
Conclusion: Apart from known predictors as age and comorbidity osteoporosis in our study was identified as a potential
independent predictor of long-term hip fracture mortality in males. This is of particular importance as treatment with
bisphosphonates after hip fracture has been shown to reduce hip fracture mortality and may be a clinical target to reduce
the burden of the disease. Further studies however are needed to confirm the validity of this finding.
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Introduction
Several studies have shown that mortality in hip fracture
patients in the middle-aged and elderly population is higher
compared to the general population and in males than in females
[1–3]. This increased mortality in hip fracture patients has been
documented in the first year after fracture and remains high in the
subsequent years of follow up [3].
Understanding which risk factors for mortality are involved in
hip fracture patients is crucial in order to reduce mortality in this
group. Pre-fracture conditions have been reported to influence the
mortality and morbidity in fragility hip fracture patients [4]. The
identified predictors of mortality include older age at fracture,
male gender [5–8], poor mental condition [7,9], pre-fracture
comorbidities (e.g. cardiovascular and pulmonary diseases)
[5,6,10], fracture site [9], complications during surgery [9], and
limited function [7]. A recent systematic review and meta-analysis
concluded that advanced age, male gender, nursing home
residence, poor preoperative walking capacity and activities of
daily living, poor mental status, dementia or cognitive impairment,
diabetes, cancer, cardiac disease and presence of multiple
comorbidities, are strongly associated with short-term increased
mortality in patients suffering a fragility hip fracture [11].
However, these studies only explored risk factors for short and
not for long-term hip fracture mortality.
Reduced bone mineral density (BMD) has been shown to be
strongly associated with increased risk for hip fracture [12] and
interestingly treatment with bisphosphonates in hip fracture
patients has been shown to reduce subsequent hip fracture
mortality [13]. However, to our knowledge, no studies have
examined the influence of osteoporosis as a risk factor for hip
fracture mortality neither in males nor in females both in the short-
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and long-term aspect. Thus, identifying osteoporosis as a potential
risk factor for mortality after hip fracture could be of great value
by detecting patients at high risk of mortality.
In this study, our primary aim was to explore for short- and
long- term risk factors of mortality in hip fracture patients in a
prospectively recruited cohort of patients followed for up to 5
years. In addition, we also explored the potential role of
osteoporosis as a risk factor for mortality after hip fracture.
Methods
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics Southern-Eastern Norway. Informed
written consent was obtained by all the participants in this study.
Identification of the Fragility Hip Fracture Patients
Patients with a fragility hip fracture aged 50 years or older
admitted to the Hospital of Southern Norway in Kristiansand in
the two year period 2004 through 2005 were prospectively
identified by trained osteoporosis nurses at our osteoporosis center.
The osteoporosis center is organized according to the fracture
liaison service model [14]. The identified patients’ medical records
and X-ray records were examined, and the diagnosis of hip
fracture was confirmed before being invited for osteoporosis
assessment as part of the clinical program for these patients.
Patients with high energy fractures, e.g. due to motor vehicle
accident, or with pathological fractures, e.g. caused by tumor,
were excluded. We also excluded patients with confusion, serious
infection and who were non-residents in the catchment area.
Patient recruitment, data collection and assessments as well as
dual-energy x-ray absorptiometry (DXA) measurements were
performed by four trained and experienced in osteoporosis nurses.
Mortality
The follow-up time for a patient was from the month that the
fracture occurred to death. For patients alive, the censoring dates
were on January 1, 2009 (recruited in 2004) and 2010 (recruited in
2005). Mortality was determined by matching the death data to
those of the Norwegian census. No data on death causes was
collected.
Demographic and Clinical Variables
Data collection included clinical assessments, standardized
questionnaires and BMD measurements (age, gender, body mass
index (BMI), osteoporosis, type of fracture, type of fracture
treatment, involvement of snow/ice, outdoors fracture, patient
discharged to home, impaired vision, cardiovascular disease,
pulmonary disease, gastrointestinal disease, kidney disease, uro-
genital disease, cancer, inflammatory joint disease, diabetes
mellitus, other endocrinopathies, dementia, stroke, other neuro-
logical disease, depression, other mental disease, alcoholism, use of
sedatives, osteoporosis treatment prior to fracture).
An overview of the variables studied is presented in Table 1.
Bone Density Measurements
Standardized BMD measurements at lumbar spine L2–4,
femoral neck and total hip on the non-fractured hip were
performed by four trained nurses by using DXA equipment,
Lunar Prodigy (General Electric) at baseline. The BMD measure-
ments were expressed as T-scores (SD) with calculations based on
the reference values in the DXA machine provided by the
manufacturer. Osteoporosis was defined as T -score #22.5,
osteopenia as T-score.22.5 and,21.0, and normal BMD a s T-
score $21.0, according to the WHO definition for osteoporosis at
spine and/or at hip [15].
Statistical Methods
The Kaplan-Meier method was used to estimate the probability
of survival 5 years after the fragility hip fracture. Intergroup
comparisons were performed using the log-rank test. For group
comparisons we applied the chi square test for categorical
variables and the Students t-test for continuous variables.
Exploring for predictors of mortality at 3 months, 1 and 5 years
after the hip fracture event, we first applied a univariate regression
model. Variables tested in the univariate model with a p value
,0.1 were then tested by adjusting for age and thereafter tested in
multivariate logistic regression using an entry procedure. A logistic
regression analysis model was applied to search for significant
predictors of mortality in the fragility hip fracture patients with
death and age as the dependent variables, and statistically
significant variables at the 0.1 level in the bivariate analysis as
the explanatory variables. The analysis was performed separately
for males and females. All the analyses were performed using the
SPSS version 17.0 (SPSS, Chicago, IL, USA). Statistical signifi-
cance was defined as p,0.05.
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We prospectively identified 432 individuals who suffered a
fragility hip fracture in the catchment area of the hospital in the
two years 2004 and 2005. One hundred and thirty six patients
[mean age 84 years (SD 7.9], 44 males [mean age 83.7 (SD 9.1)]
and 92 females [mean age 84.3 (SD 7.3)] were not assessed at the
osteoporosis center of Kristiansand Hospital due to severe
confusion or serious infection. The 296 patients [mean age 80.7
(SD 9.1)] who were assessed at the osteoporosis center included in
this study, 86 males [mean age 80.0 years (SD 8.9)] and 211
females [mean age 80.9 years (SD 9.2)] were interviewed,
examined by the trained nurses and measured by DXA. Patients
not assessed at the osteoporosis center were in mean 3.5 years
older (p,0.0005) [males 3.7 years (p = 0.014) and females 3.1
years (p = 0.006)]. There were no significant gender differences
between patients assessed and not assessed at the osteoporosis
center (29% vs. 32% for males and 71% vs. 68% for females,
p = 0.443).The baseline characteristics of the assessed patients are
presented in Table 1.
Mortality of the Fragility Hip Fracture Patients
Three months after the hip fracture event 12 males (14.1%) and
5 females (2.1%) were dead (p,0.01) and after one year 22 males
(25.9%) and 21 females (10.0%) were dead (p,0.01). Five years
after the fragility hip fracture 60 males (70.6%) and 102 females
(48.3%) in the cohort group had died (p,0.01). For the patients
not assessed at the osteoporosis center the corresponding death
figures were for 3 months, 1 year and 5 years follow up 13 (29%),
26 (59%) and 39 (87%) for males and 18 (24%), 37 (40%) and 75
(81%) for females. The log-rank analysis showed a statistically
significant difference between the two groups in both males and
females (p,0.001) (Fig. 1).
Predictors of Mortality in Hip Fracture
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Univariate Analysis and Analysis Adjusted for Age
In the univariate analysis, for the short- term mortality
(3 months), osteoporosis treatment in females and dementia,
gastrointestinal diseases, no involvement of snow or ice, indoor
activity, impaired vision, stroke and age .80 years in males were
significantly associated with death. For short-term mortality
(1 year) the associations included indoor activity, osteoporosis
treatment, and age .80 years in females and discharge to home,
indoor activity, stroke, neurologic disease, pulmonary disease and
no involvement of snow or ice in males. Variables significantly
associated with long-term mortality (5 years) included no involve-
ment of snow or ice, indoor activity, osteoporosis, dementia, visual
impairment, use of sedatives, discharge to home and age .80
years for females and no involvement of snow or ice, indoor
activity, osteoporosis, dementia, cancer stroke and age in males.
No associations were observed with regard to cardiovascular
diseases, diabetes mellitus, other endocrinopathies, depression,
other mental diseases, alcoholism, type of fracture, type of fracture
treatment, BMI, weight and BMD of spine (L2–L4), and right or
left hip. In the age-adjusted univariate analysis of 5 years
associations, variables significantly associated were no involvement
of snow or ice and osteoporosis in males, and in females no
Table 1. Baseline characteristics of 296 patients assessed at the osteoporosis center suffering a fragility hip fracture in 2004 and
2005.
Characteristics All patients (n = ) Males (n= ) Females (n = ) P values
Age (years) 80.6 (9.1) 80 (8.9) 81 (9.2) 0.47
Gender 296 85 (28.7) 211 (71.3)
.80 years 173 46 (54.1) 127 (60.0) 0.33
Body mass index kg/m2 22.9 (3.7) 23 (3.6) 22.7 (3.8) 0.21
Osteoporosis 218 (73.6) 53 (62.4) 165 (78.9) ,0.01
Type of hip fracture
Neck 200 (67.6) 62 (72.9) 138 (65.4) 0.134
Per-trochanteric 88 (29.7) 23 (27.1) 65 (30.8)
Sub-trochanteric 8 (2.7) 0 8 (3.8)
Type of treatment
Not operated 10 (3.4) 3 (3.5) 7 (3.3) 0.20
CHP 163 (55.1) 54 (63.5) 109 (51.6)
DHS 107 (36.1) 26 (31.0) 81 (38.3)
Total or hemi-prosthetic joint 16 (5.1) 2 (2.4) 14 (6.7)
Cardiovascular disease 145 (49.0) 40 (47.1) 105 (50.0) 0.64
Pulmonary disease 46 (15.5) 17 (20.0) 29 (13.8) 0.18
Gastrointestinal disease 37 (12.5) 14 (16.5) 23 (11.0) 0.19
Kidney disease 7 (2.4) 6 (7.1) 1 (0.5) ,0.01
Inflammatory joint disease 27 (9.1) 6 (7.1) 21 (10.0) 0.43
Diabetes mellitus 18 (6.1) 7 (8.2) 11 (5.2) 0.32
Depression 14 (4.7) 3 (3.5) 11 (5.2) 0.53
Endocrinopathies (other) 35 (11.8) 10 (11.8) 25 (11.9) 0.97
Neurological disease (other) 72 (24.3) 22 (25.9) 50 (23.8) 0.70
Urogenital disease 26 (8.8) 17 (20.0) 9 (4.3) ,0.01
Dementia 30 (10.1) 8 (9.4) 22 (10.5) 0.78
Stroke 29 (9.8) 9 (10.6) 20 (9.5) 0.77
Mental disease (other) 14 (4.7) 3 (3.5) 11 (5.2) 0.53
Cancer 39 (13.2) 15 (17.6) 24 (11.4) 0.15
Alcoholism 3 (1.0) 2 (2.4) 1 (0.5) 0.14
Sedatives 50 (16.9) 9 (10.6) 41 (19.4) 0.06
Snow/ice involved 45 (15.2) 24 (28.2) 21 (10.0) 0.01
Outdoors fracture 89 (30.1) 34 (40.0) 55 (26.1) ,0.01
Discharged at home 89 (30.1) 30 (35.7) 59 (28.0) 0.19
Impaired vision 9 (3.0) 3 (3.5) 6 (2.9) 0.76
Osteoporosis treatment 18 (6.1) 4 (5.6) 14 (8) 0.50
Continuous variables are presented as mean with standard deviation (SD) and categorical variables as numbers and percentage. For group comparison independent
sample t-tests were applied for continuous variables and chi-square tests for categorical variables.
SD: Standard deviation, CHP: Cannulated hip screw DHS: Dynamic hip screw.
doi:10.1371/journal.pone.0078169.t001
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involvement of snow or ice, dementia, use of sedatives and indoor
activity, as shown in table 2 and 3.
Multivariate Logistic Regression Analysis
In the logistic regression analysis model, no associations were
observed neither for females or males for the 3 months after the
fragility hip fracture (data not shown). Variables associated with
short-term mortality (1 year) were age .80 years in females (OR
6.95) and age .80 years (OR 5.74) and pulmonary disease (OR
3.20) in males. Variables associated with 5 years mortality were
age .80 years, dementia in females (table 2) and age .80 years
and osteoporosis in males (Table 3).
Discussion
In our study, aiming to identify predictors of mortality in hip
fracture patients, older age and comorbidities was found to be
associated with increased risk of death both after 1 and after 5
years of follow up. However, none of the examined potential risk
factors was found to be independently associated with death after 3
months when tested in multivariate analysis, not even age. We
found osteoporosis to be associated with 5 years mortality in
univariate analysis for both men and women. When adjusting for
age, osteoporosis remained statistically significant for males and
was borderline significant associated with increased risk of death in
females. In men but not in women, osteoporosis even remained
independently associated with increased 5 years mortality.
To our knowledge, this is the first study to examine the direct
contribution of osteoporosis as a risk factor for mortality in hip
Figure 1. Kaplan-Meier survival curves of male and female hip fracture patients prospectively recruited into the prospective
osteoporosis cohort compared to those excluded from the study.
doi:10.1371/journal.pone.0078169.g001
Table 2. Univariate, age-adjusted, and multivariate logistic regression analysis showing associations between the different factors
and the dependent variable of the study (mortality) in males 5 years after the hip fracture.
Univariate model Age adjusted Multivariate model
P values OR (95% C.I.) P values OR (95% C.I.) P values OR (95% C.I.)
Age (ref group,80) ,0.0005 8.63 (2.81–26.47) – – 0.004 6.95 (1.88–25.58)
Stroke (ref. group no) 0.041 1.17 (1.05–1.30) 0.99 N/A 0.99 N/A
Cancer (ref. group no) 0.033 7.30 (0.90–58.93) 0.08 6.9 (0.8–61.3) 0.53 2.08 (0.20–20.73)
Dementia (ref. group no) 0.055 1.15 (1.04–1.27) 0.99 N/A 0.99 N/A
Snow/ice involved (ref. group no) ,0.0005 0.44 (0.23–0.84) 0.006 0.22 (0.06–0.63) 0.053 0.13 (0.01–1.01)
Outdoor fracture (ref. group no) 0.004 0.24 (0.09–0.64) 0.06 0.35 (0.12–1.05) 0.36 2.44 (0.35–16.97)
Osteoporosis (ref. group no) 0.001 4.88 (1.80–13.25) 0.01 4.2 (1.40–12.63) 0.03 3.91 (1.08–14.08)
OR: odds ratio, C.I.: confidence interval, ref.: reference.
doi:10.1371/journal.pone.0078169.t002
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fracture patients. This is an interesting finding as treatment with
bisphosphonates after hip fracture has been shown to reduce
mortality [13] and may be a clinical target to reduce the burden of
the disease. Males have higher mortality rates and are in greater
risk of institutionalization than females [16]. Hence, the observed
3-fold increase in long-term mortality of the fragility hip fracture,
could explain the higher mortality rates and maybe predict a
greater efficacy of anti-osteoporosis treatment [17] in this group of
patients.
Older age is a strong predictor of mortality in both genders [5–
8,11]. It seems that the frail older population is most sensitive to
the complications related to the fracture event [18]. As the aging
population is steadily growing in Western societies, intense efforts
are warranted in order to reduce the number of hip fractures in
this group of patients.
In our study, we also found other risk factors associated with
increased mortality after hip fracture. Dementia in females was
found to be associated with 5 years mortality, increasing the death
risk by approximately 4 times (Table 3). Nevertheless, dementia
was not associated with increased mortality neither 3 months nor 1
year after the event. This is in agreement with previous published
studies, which have shown no association between reduced mental
status and the short-term mortality of hip fracture [8,19].
However, this is in contrast with other studies, showing a clear
contribution of the reduced mental status in the mortality rates in
females [7,11]. One explanation could be that we excluded all
patients with a severe deterioration of their mental status after hip
fracture. Delirium during the perioperative period seems to be
associated with severe worsening of cognitive functions and is a
strong predictor of short-term mortality in fragility hip fracture
patients [8].
With regard to other pre-fracture comorbidities, we found
pulmonary disease to be associated with increased mortality in
males and this was only one year after fracture. This has also been
described elsewhere [10,20]. While in some studies a clear
association with comorbidities (e.g. cardiovascular) was demon-
strated, we were not able to demonstrate any other associations in
short or long-term mortality with increased risk of mortality after
hip fracture. The above findings explain only partially the
increased mortality in males suffering a fragility fracture in short-
and long-term aspects. However, prevention and treatment of
pulmonary diseases in males should be emphasized in order to
reduce the risk of death in short-term. Our data adds evidence that
reduced health condition prior to fracture in an individual with a
hip fracture increases mortality risk.
In our study, we did not observe any influence of osteoporosis
treatment neither in males nor in females both for short- and long-
term mortality. This may be explained by the fact that our study
including a rather small number of patients and was not designed
to investigate the impact of osteoporosis treatment. In other
studies, a reduced mortality rate has been reported in patients
treated with bisphosphonates [13] [21,22]. A disappointing finding
in our research is that despite osteoporosis being established in up
to 79% of females and 62% of males patients only 8% of females
and 6% of males received osteoporosis treatment.
We did not observe any influence in hip fracture mortality of the
type of fracture or surgical treatment selected neither on males nor
on females. This finding is in agreement with previous published
studies [10,23].
Limitations
Our study has limitations. A significant part of the fragility hip
fracture patients (31%) were not assessed at the osteoporosis
center. This group was significantly older than and had a higher
mortality than patients assessed at the osteoporosis center as shown
in Figure 1. Therefore, it is reasonable to believe that the major
part of the frailest of patients was not included in our analysis. For
that reason, our results could be influenced by selection bias as in
our cohort we included the healthiest of the fragility hip fracture
patients. The above selection could also explain the lack of
association between comorbidities and increased short- and long-
term mortality.
In conclusion, high age and comorbidities were found to be
predictors of mortality in hip fracture patients not only in the first
year but also at five years of follow up. Our data indicates that
osteoporosis is a risk factor for long-term mortality in hip fracture
patients. This finding was more significant in males than in
females. Further studies however are needed to confirm the
validity of this finding.
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